Literature DB >> 26385369

Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Casper Webers1, Ivette Essers2, Sofia Ramiro3, Carmen Stolwijk2, Robert Landewé4, Désirée van der Heijde3, Filip van den Bosch5, Maxime Dougados6, Astrid van Tubergen7.   

Abstract

OBJECTIVES: To investigate gender-attributable differences regarding clinical outcome [disease activity, physical function and quality of life (QoL)] and radiographic damage in patients with AS over time.
METHODS: Data from the Outcome in AS International Study were used. Disease activity was assessed by the BASDAI, ASDAS and CRP; physical function by BASFI; QoL by the Short Form-36, Ankylosing Spondylitis Quality of Life (ASQoL) score and European Quality Of Life scale; and radiographic damage by the modified Stoke AS Spine Score (mSASSS). Cross-sectional comparative analyses were done at baseline. Next, separate models were created to assess gender-attributable differences on each outcome measure over time using time-adjusted generalized estimating equations.
RESULTS: A total of 216 patients [154 (72.3%) males, mean age 43.6 years (s.d. 12.7), symptom duration 20.5 years (s.d. 11.8), mean follow-up duration 8.3 years (s.d. 4.1)] were included. At baseline, male compared with female patients had lower self-reported disease activity (BASDAI 3.2 vs 3.9, P = 0.03) but more radiographic damage (mSASSS 13.8 vs 6.5, P = 0.02). No significant gender-attributable differences in other clinical parameters were found. In multivariable analysis, male gender was significantly associated with a better ASQoL (B = -1.18, 95% CI: -2.17, -0.20, P = 0.02), and in a separate model with a higher mSASSS over time (B = 8.24, 95% CI: 4.38, 12.09, P < 0.01).
CONCLUSION: In this prospective cohort study, no gender-attributable differences in disease activity or physical function over time were found. However, radiographic damage was more severe in males. Furthermore, males had a better QoL over time.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ankylosing spondylitis; epidemiology; gender; longitudinal studies; sex

Mesh:

Substances:

Year:  2015        PMID: 26385369     DOI: 10.1093/rheumatology/kev340

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  40 in total

1.  Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.

Authors:  Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Merih Birlik; Fatoş Önen
Journal:  Rheumatol Int       Date:  2018-09-08       Impact factor: 2.631

Review 2.  The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis.

Authors:  Xiao Yang; Dazhi Fan; Qing Xia; Mengmeng Wang; Xu Zhang; Xiaona Li; Guoqi Cai; Li Wang; Lihong Xin; Shengqian Xu; Faming Pan
Journal:  Qual Life Res       Date:  2016-06-20       Impact factor: 4.147

3.  The disease burden of axial spondyloarthritis: through a gendered lens.

Authors:  Sara Khan; Divya Shridharmurthy; Kate L Lapane; Catherine Dube; Jonathan Kay; Esther Yi; Shao-Hsien Liu
Journal:  Clin Rheumatol       Date:  2022-01-06       Impact factor: 2.980

Review 4.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

5.  Trends in hospitalizations for vertebral compression fracture in ankylosing spondylitis: data from the National Inpatient Sample 2000-2014.

Authors:  Rashmi Dhital; Ibiyemi Oke; Anthony Donato; Anish Paudel; Dilli Ram Poudel; Prakash Paudel; Paras Karmacharya
Journal:  Clin Rheumatol       Date:  2021-07-05       Impact factor: 2.980

6.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

7.  Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage.

Authors:  Clementina López-Medina; Juan L Garrido-Castro; Juan Castro-Jiménez; Cristina González-Navas; Jerusalem Calvo-Gutiérrez; M Carmen Castro-Villegas; Rafaela Ortega-Castro; Alejandro Escudero-Contreras; Pilar Font-Ugalde; Eduardo Collantes-Estévez
Journal:  Clin Rheumatol       Date:  2018-04-24       Impact factor: 2.980

Review 8.  Exercise programmes for ankylosing spondylitis.

Authors:  Jean-Philippe Regnaux; Thomas Davergne; Clémence Palazzo; Alexandra Roren; François Rannou; Isabelle Boutron; Marie-Martine Lefevre-Colau
Journal:  Cochrane Database Syst Rev       Date:  2019-10-02

9.  Ankylosing spondylitis risk factors: a systematic literature review.

Authors:  Mark C Hwang; Lauren Ridley; John D Reveille
Journal:  Clin Rheumatol       Date:  2021-03-22       Impact factor: 3.650

10.  IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients.

Authors:  Milena Iwaszko; Joanna Wielińska; Jerzy Świerkot; Katarzyna Kolossa; Renata Sokolik; Bartosz Bugaj; Monika Chaszczewska-Markowska; Sławomir Jeka; Katarzyna Bogunia-Kubik
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.